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Abstract
Background: While poor sleep quality can worsen cardiovascular risk factors such as glucose and lipid profiles in
patients with type 2 diabetes mellitus (T2DM), the relationship between sleep quality and atherosclerosis remains
largely unknown. The aim of this study was to examine this relationship.
Methods: The study participants comprised 724 Japanese T2DM outpatients free of history of cardiovascular diseases.
The relationships between sleep quality (assessed by the Pittsburgh Sleep Quality Index (PSQI)) and various clinical and
laboratory parameters were investigated.
Results: The mean PSQI was 5.1 ± 3.0 (±SD). Patients were divided into three groups based on the total PSQI score;
subjects with good sleep quality (n = 462), average sleep quality (n = 185), and poor sleep quality (n = 77). In the
age/gender-adjusted model, patients with poor sleep quality tended to be obese, evening type and depressed.
However, other lifestyles showed no significant trends. Alanine aminotransferase, fasting blood glucose, HbA1c,
systolic blood pressure, urinary albumin excretion, and brachial-ankle pulse wave velocity (baPWV) tended to be
higher in patients with poor sleep quality. High baPWV was the only parameter that correlated with poor sleep in a
model adjusted for several other lifestyle factors.
Conclusions: Our study indicates that poor sleep quality in T2DM patients correlates with increased arterial wall
stiffness, a marker of atherosclerosis and a risk factor for cardiovascular diseases.
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Background
The onset and development of type 2 diabetes mellitus
(T2DM) is associated with numerous lifestyle factors. Fur-
thermore, the risk of cardiovascular disease (CVD) and
microvascular events in patients with T2DM correlate
with such lifestyle factors [1, 2]. Evidence suggests that
poor sleep quality is an important pathological factor in
the onset of T2DM [3–9] and also in CVD [10] in non-
T2DM subjects. On the other hand, patients with T2DM
are reported to have various sleep abnormalities compared
to healthy control subjects [11]. Furthermore, recent
studies reported that short sleep and/or lack of deep sleep
are risk factors for hyperglycemia [12–14], hyperlipidemia
[15, 16] and renal dysfunction [17]. However, little is
known at present about the relation between poor sleep
quality and progression of atherosclerosis in patients with
T2DM.
The brachial-ankle pulse wave velocity (baPWV) is a
noninvasive technique for assessment of arterial wall
stiffness. It is often used clinically to evaluate the state of
atherosclerosis and prediction of CVD in both non-
diabetic [18, 19] and T2DM patients [20, 21].
The purpose of the present study was to determine
the impact of poor sleep quality on various parameters,
including arterial wall stiffness, in patients with T2DM.
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The subjects of this cohort study were recruited from
the Diabetes Outpatient Clinic of Juntendo University
(Tokyo, Japan), Naka kinen Clinic (Naka, Japan), and
Secomedic Hospital (Funabashi, Japan) [22]. The inclu-
sion criteria were as follows: 1) T2DM male and female
patients, 2) ≥25 years of age and <70 years of age, and 3)
signing consent form for participation in the study. The
following exclusion criteria were also applied: 1) type 1
or secondary diabetes, 2) presence of severe infection,
recent surgery, and severe trauma, 3) history of myocar-
dial infarction, angina pectoris, or stroke, 4) chronic
renal failure requiring hemodialysis, 5) liver cirrhosis, 6)
moderate or severe heart failure (NYHA/New York
Heart Association stage III or higher), 7) active malig-
nancy, 8) pregnancy, lactation, or possible pregnancy, 9)
patients judged as ineligible by the clinical investigators.
A total of 1032 consecutive subjects were screened.
Among them, 906 patients who met the above eligibility
criteria were invited to participate in the present study.
After providing information on the purpose and proce-
dures of the study, 736 patients with T2DM were en-
rolled in this study between June 2013 and January 2014.
The study was approved by the Institutional Review
Board of our hospital and conducted in accordance with
the principles described in the Declaration of Helsinki.
All patients provided written informed consent prior to
participation. The study was registered on the University
Hospital Medical Information Network Clinical Trials
Registry (UMIN000010932).
Questionnaire survey
The self-administered questionnaire survey used in the
present study was the Pittsburgh Sleep Quality Index
(PSQI) [22, 23], which has been validated previously
[22]. It is used to evaluate sleep quality and consists of
18 items that in turn are comprised of 7 components
covering subjective sleep quality, sleep duration, sleep
onset, habitual sleep efficiency, sleep disturbances, use of
sleeping medications, and daytime dysfunction. Each
component is weighted equally on a 0–3 scale, and
summed to yield the total PSQI score (range, 0–21), with
the highest score denoting worst sleep quality. Based on
the total PSQI score, patients were divided into three
groups; the “Good sleep quality group” with PSQI score
of ≤5: “Average sleep quality group” with PSQI 6–8, and
“Poor sleep quality group” with PSQI ≥9 [14].
We also used the Morning Evening Questionnaire
(MEQ) [24] to evaluate morningness and eveningness in
individuals. A high MEQ score represents morning type.
The participating patients also completed the BDI (Beck
Depression inventory)-II, which is a 21-item question-
naire that assesses hopelessness, irritability, cognition,
guilt, fatigue, weight loss, and sexual interest, represent-
ing depression-related symptoms [25]. A high BDI score
represents depressive state. Dietary habits during the
preceding month were also assessed by the self-
administered Diet History Questionnaire (BDHQ).
Briefly, the 4-page structured BDHQ includes questions
on selected foods and is designed to estimate the dietary
consumption of 56 food and beverage items [26]. Phys-
ical activity level was assessed with the 4-question Inter-
national Physical Activity Questionnaire (IPAQ) [27],
and the results were expressed as metabolic equivalent
scores (METs-hour-week−1). In the above questionnaires,
workers were defined as full-time employees or shift
workers [22]. The subjects were also divided into non-
smokers, former smokers or current smokers [22].
Blood and urine tests
Blood samples were collected at the Outpatient Clinic after
overnight fast. Liver and renal function tests, lipid profile,
HbA1c (National Glycohemoglobin Standardization
Program), and blood glucose were measured with stand-
ard techniques. UAE was measured by the latex agglu-
tination assay using a spot urine sample. The estimated
glomerular filtration rate (eGFR) was calculated by the
formula: eGFR (ml/min per 1.73 m2) =194× Age-0.287×
serum creatinine-0.1094 (×0.739 for females) [28].
Measurement of baPWV
baPWV was measured using an automatic waveform
analyzer (BP-203RPE; Colin Medical Technology, Komaki,
Japan), as described previously [22, 29]. Briefly, recording
was performed with the patients in the supine position
after 5-min rest. Occlusion and monitoring cuffs were
placed snugly around both areas in the upper and lower
extremities. The pressure waveforms were then recorded
simultaneously from the brachial arteries by the oscillo-
metric method. All scans were automatically conducted
by well-trained investigators who were blinded to the clin-
ical information. Previous studies confirmed the validity
and reproducibility of baPWV measurements [30]. The
ankle-brachial index was measured in all participants. A
resting ankle-brachial index ≤ 0.90 was considered to reflect
the presence of peripheral artery disease. Subjects with
baPWV-determined peripheral artery disease underwent
computed tomographic angiography, magnetic resonance
angiography or catheter angiography to confirm the diag-
nosis of peripheral artery disease. Arterial stenotic lesions
represented arterial lumen narrowing of ≥50 %. Six patients
with peripheral artery disease were excluded from analysis.
Statistical analysis
Results are presented as mean ± SD or median (inter-
quartile range: 25 to 75 %) for continuous variables or
number (proportion) of patients for categorical variables.
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Several parameters were logarithmically transformed to
approximate normal distribution. Trend association
across the three PSQI score-based groups was evaluated
by linear regression analysis for continuous variables and
logistic regression analysis for categorical variables. We
developed three models to evaluate the trend. The first
model was unadjusted, the second was adjusted for age
and gender but not eGFR, and the third model was ad-
justed for age, gender, body mass index (BMI), MEQ,
BDI-II, energy intake, smoking pattern, alcohol consump-
tion and IPAQ. The final model for baPWV was adjusted
for age, gender, BMI, MEQ, BDI-II, energy intake, smok-
ing pattern, alcohol consumption, IPAQ, systolic blood
pressure (SBP), HbA1c, total cholesterol, high-density
lipoprotein cholesterol (HDL) cholesterol, triglyceride and
sleep duration. Statistical tests were two-sided with 5 %
significant level. All analyses were performed using the
SAS software version 9.3 (SAS Institute, Cary, NC).
Results
Among the 736 participating patients, 12 did not
complete the PSQI questionnaires and they were thus
excluded from this analysis. The characteristics of the
remaining 724 Japanese patients with T2DM are shown in
Table 1. The mean age was 57.8 ± 8.6 years, and 62.9 %
subjects were males. The mean HbA1c was 7.0 ± 1.0 %,
and the estimated duration of T2DM was 9.9 ± 7.2 years.
Most subjects had previously attended educational pro-
grams about diet and exercise therapy and received appro-
priate medical treatments. Thus, blood glucose levels,
lipid profile, and SBP were well controlled.
Based on the results of the PSQI, 462 individuals were
categorized into the “Good sleep quality group”, 185 into
the “Average sleep quality group”, and 77 into the “Poor
sleep quality group” (Table 2). Subjects with poor sleep
quality tended to be younger, female and obese, and had
low MEQ and high BDI-II in the unadjusted model. In
the age/gender-adjusted model, they still tended to be
more obese, had low MEQ and high BDI-II. On the
other hand, no significant trends were found in other
lifestyles including energy intake, smoking, alcohol con-
sumption and IPAQ. In both the unadjusted and age/
gender-adjusted models, subjects with poor sleep quality
type were likely to go to bed late at night, wake up late,
sleep for short time and less frequently had breakfast.
However, these findings were not observed in the model
adjusted for age, gender, BMI, MEQ, BDI-II, energy in-
take, smoking, alcohol consumption and IPAQ.
With regard to clinical and laboratory data, patients
with poor sleep quality tended to have high levels of ala-
nine aminotransferase (ALT), total cholesterol, fasting
blood glucose, HbA1c, SBP and UAE in the unadjusted
model (Table 3). Even in the age/gender adjusted model,
ALT, fasting blood glucose, HbA1c, SBP, UAE, and
baPWV tended to be higher in patients with poor sleep
quality than the other two groups. Intriguingly, a high
baPWV level was the only factor related to patients with
poor sleep quality in the adjusted model by age, gender,
BMI, MEQ, BDI-II, energy intake, smoking, alcohol con-
sumption and IPAQ. Furthermore, baPWV tended to be
higher in patients with poor sleep quality than the other
two groups even in SBP, HbA1c, total cholesterol, HDL-
cholesterol, triglyceride and sleep duration, which are po-
tential risk factors for arterial stiffness, and age, gender,
BMI, MEQ, BDI-II, energy intake, smoking consumption,
alcohol consumption and IPAQ adjusted model.
Table 1 Patients’ characteristics (n = 724)
Age (years) 57.8 ± 8.6
Gender (male) 456 (62.9)
Estimated history of diabetes (years) 9.9 ± 7.2
Body mass index (kg/m2) 24.6 ± 4.1
HbA1c (%) 7.0 ± 1.0
HbA1c (mmol/mol) 52.5 ± 10.8
Fasting blood glucose (mg/dl) 134 ± 31
Systolic blood pressure (mmHg) 127 ± 14
Diastolic blood pressure (mmHg) 77 ± 11
Total cholesterol (mg/dL) 185 ± 28
HDL-cholesterol (mg/dL) 59 ± 14
Triglyceride (mg/dL) 100 [70,152]
AST (U/L) 21 [18, 27]
ALT (U/L) 22 [16, 33]
γ-GTP (U/L) 25 [17,39]
Uric Acid (mg/dl) 5.5 ± 1.2
eGFR (ml/min/1.73 m2) 78 ± 18
UAE (mg/g creatinine) 10 [6, 23]
baPWV (cm/s) 1543 ± 279
Morningness-Eveningness Questionnaire 57.4 ± 7.3
Pittsburgh Sleep Quality Index 5.1 ± 3.0
Beck Depression inventory -II 9.9 ± 7.6
Energy intake (kcal/day) 1713 ± 582
Physical activity (Mets/h/week) 42.8 ± 70.5
Sleep duration (hours) 6.4 ± 1.2
Current smoker (yes) 174 (24.0)
Alcohol (g/day) 12.3 ± 21.5




Data are mean ± SD or number (proportion) of patients
ALT alanine aminotransferase, AST aspartate aminotransferase, baPWV
brachial-ankle pulse wave velocity, eGFR estimated glomerular filtration rate,
HDL-C high-density lipoprotein-cholesterol, UAE urinary albumin excretion,
γ-GTP γ-glutamyl transpeptidase
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Discussion
The main finding of this study was that poor sleep qual-
ity correlated with arterial stiffness in patients with
T2DM, even after adjustment for other lifestyle factors
and risk factors for atherosclerosis. Another important
finding was that poor sleep quality also correlated with
various cardiovascular risk factors, such as poor gly-
cemic control, high lipid profile, high SBP, and high ALT
and UAE. However, these relationships disappeared after
adjustment for other lifestyle factors.
Our study showed that poor sleep quality was associ-
ated with increased arterial stiffness after adjustment for
multi-covariates including other life style factors. This
association was still significant even after adjustment
for potential risk factors for arterial stiffness in addition
to other life style factors. These findings suggest that
poor sleep quality may have some direct influence on
arterial stiffness independent of cardiovascular risk fac-
tors. While the potential mechanism(s) linking poor
sleep quality and arterial stiffness remains largely un-
known, high levels of catecholamines due to poor qual-
ity and/or duration of sleep may play a role in the
progression of arterial stiffness, as reported previously
[31, 32]. In this regard, one previous study demon-
strated that sympathetic activation may negatively influ-
ence arterial stiffness in human, independent of BP [33].
High catecholamine levels induced by sympathetic
nerve activation may promote smooth muscle cell pro-
liferation and fibrosis, which in turn contribute to struc-
tural changes in the arterial wall.
Table 2 Characteristics of subjects of the three sleep quality groups
Variable
Sleep quality group
Unadjusted Model 1 Model 2Good (n = 462) Average (n = 185) Poor (n = 77)
PSQI 3.4 ± 1.3 6.8 ± 0.8 11.5 ± 2.9 - - -
Sleep duration (hours) 6.8 ± 1.0 6.0 ± 1.0 5.3 ± 1.1 −13.60*** −13.12*** −13.72***
Wake time, A.M. 6:00 [5:30,6:30] 6:00 [5:30,6:30] 6:00 [5:30,7:00] 2.20* 2.06* 0.79
Bed time, P.M. 23:00 [22:00,23:30] 23:30 [22:30,24:00] 23:30 [22:00,24:00] 2.91** 2.12* 0.79
MEQ 58.6 ± 7.1 55.4 ± 7.2 54.9 ± 7.2 −5.81*** −5.14*** -
BDI 8.0 ± 6.7 12.5 ± 7.8 15.1 ± 8.4 9.65*** 9.23*** -
Energy intake (kcal/day) 1692 ± 542 1760 ± 646 1726 ± 650 1.00 1.70 -
Current smoking (yes) 114 (24.7) 42 (22.7) 17(22.1) −0.64 −0.44 -
Alcohol 12.5 ± 21.1 10.2 ± 20.9 16.3 ± 24.7 0.59 1.76 -
Physical activity (kcal/day) 41.6 ± 65.1 47.9 ± 86.2 38.7 ± 59.2 0.22 0.42 -
Age (years) 58.4 ± 8.6 56.3 ± 8.5 57.2 ± 8.0 −2.25* - -
Gender (male) 304 (65.8) 111 (60.0) 40(51.9) −2.48* - -
Body mass index (kg/m2) 24.4 ± 4.0 24.8 ± 4.1 25.8 ± 4.4 2.93** 2.21* -
Estimated duration of diabetes (years) 10.0 ± 7.4 9.2 ± 6.1 10.8 ± 8.6 0.16 0.75 −0.25
Diabetes medication (yes) 395 (85.5) 156 (84.3) 68 (88.3) 0.34 0.41 0.37
Hypertension medication (yes) 212 (45.9) 93 (50.3) 41 (53.2) 1.42 1.70 0.61
Dyslipidemia medication (yes) 290 (62.8) 103 (55.7) 48 (62.3) −0.84 −0.94 −1.30
Anti-platelet (yes) 14 (3.0) 4 (2.2) 5 (6.5) 1.00 1.46 1.18
Working (yes) 334 (72.3) 136 (73.5) 62 (80.5) 1.35 1.50 1.11
Shift worker (yes) 43 (9.3) 23 (12.4) 12 (15.6) 1.84 1.41 1.60
Breakfast time, A.M. 7:00 [6:30,7:30] 7:00 [6:30,7:30] 7:18 [6:30,8:00] 3.75*** 3.30** 1.96
Dinner time, P.M. 19:00 [18:30,19:30] 19:00 [18:30,20:00] 19:00 [18:30,20:00] 3.32*** 3.00** 1.90
Time of breakfast (/week) 6.7 ± 1.0 6.4 ± 1.5 6.3 ± 1.7 −3.36*** −3.16** −0.64
Late evening snack (yes) 178 (38.5) 76 (41.1) 34 (44.2) 1.02 0.87 0.14
Data are mean ± SD or median (range: 25 to 75 %) or number of subjects
Unadjusted and Adjusted Ptrend values for linear trends across three groups are based on linear regression analysis for continuous variables or logistic regression
analysis for categorical variables. Model 1 and Adjusted values for linear trends across three groups are based on linear regression analysis for continuous
variables or logistic regression analysis for categorical variables adjusted for age and gender. Model 2 and Adjusted Ptrend values for linear trends across three
groups are based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables adjusted for age, gender, BMI,
morningness-eveningness questionnaire, Beck Depression inventory, energy intake, alcohol intake, current smoking, and physical activity
*P < 0.05; **P < 0.01; ***P < 0.001
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Our study also showed that a large proportion of T2DM
had a PSQI score of more than 6 points, confirming the
findings of previous studies [13, 14, 16]. In addition, pa-
tients with poor sleep quality, tended to have high levels
of ALT, total cholesterol, fasting blood glucose, HbA1c,
SBP and UAE, which is almost similar to the findings of
previous studies [13, 14, 16]. However, in the above previ-
ous studies, other life style factors, such as diet, physical
activity, chronotype and depressive state, were not fully
taken into consideration. In the present study, which
checked other life style factors, we investigated the rela-
tionship between poor sleep quality and cardiovascular
risk factors. The results showed no relation between poor
sleep quality and any of the cardiovascular risk factors.
This finding suggests that various life style factors, in
addition to poor sleep quality, contribute to worsening
cardiovascular risk factors. In fact, patients with poor sleep
quality tended to be more evening type and in depressive
state. Recently, we and other groups reported the relation-
ship of evening type to inadequate glycemic control in
patients with T2DM [22, 34, 35]. In addition, depressive
status could also negatively affect glucose metabolism
based on the findings that increased counter-regulatory
hormones present in the depressive state negatively affect
glucose metabolism [36]. Thus, these factors in patients
with poor sleep can negatively affect glucose metabolism.
The present study has certain limitations. First, the
cross-sectional design does not allow inference of causal
relationship between sleep quality and arterial stiffness.
Second, we evaluated lifestyles including PSQI by self-
reported questionnaires. The results could be influenced
by social desirability and recall bias. Third, the validity
and reproducibility of the lifestyle patterns identified in
this study were not confirmed, although we used valid
and reliable life-related self-reported questionnaires.
Fourth, we only used evaluation of arterial stiffness to
assess atherosclerosis. It is important to validate the
current findings using other techniques. The exclusion
of subjects with history of CVD may have influenced the
results. However, we are currently conducting long-term
follow-up study that focuses on lifestyle and onset of pri-
mary CVD in the same cohort. This study might provide
further information about the relationship between sleep
quality and primary CVD in T2DM patients. Finally, we
cannot exclude the possible effects of other lifestyle pat-
terns that were not assessed in this study.









Good (n = 462) Average (n = 185) Poor (n = 77)
AST (U/L) 21 [18, 27] 21 [18, 26] 22 [18, 27] 1.15 1.30 0.57 -
ALT (U/L) 22 [16,33] 22 [17,33] 25 [17,35] 2.18* 2.00* 1.07 -
γ-GTP (U/L) 25 [17,37] 25 [18,42] 26 [16,42] 0.95 1.40 0.03 -
Uric acid (mg/dl) 5.5 ± 1.2 5.4 ± 1.2 5.4 ± 1.4 −0.86 −0.21 −1.13 -
eGFR (ml/min/1.73 m2) 78 ± 18 79 ± 18 78 ± 19 0.65 - 0.55 -
Total cholesterol (mg/dl) 184 ± 28 188 ± 28 189 ± 25 2.04* 1.66 1.63 -
HDL-C (mg/dl) 59 ± 14 59 ± 14 61 ± 14 0.60 0.47 0.77 -
Triglycerides (mg/dl) 99 [68,150] 102 [72,148] 105 [74,158] 1.23 1.09 0.10 -
Fasting blood glucose (mg/dl) 132 ± 31 136 ± 31 141 ± 32 2.61** 2.41* 1.21 -
HbA1c (%) 6.9 ± 1.0 7.1 ± 1.1 7.1 ± 0.8 2.56* 2.01* 1.38 -
HbA1c (mmol/mol) 51.7 ± 10.6 54.0 ± 11.9 54.1 ± 9.0 2.56* 2.01* 1.38 -
Systolic BP (mmHg) 126 ± 14 127 ± 15 131 ± 13 3.07** 3.06* 1.95 -
Diastolic BP (mmHg) 77 ± 11 77 ± 11 79 ± 12 1.53 1.53 0.61 -
UAE (mg/g creatinine) 10 [6,21] 10 [6,25] 16 [7,40] 2.19* 2.23* 1.25 -
baPWV (cm/s) 1523 [1500, 1547] 1570 [1533, 1606] 1604 [1547, 1661] - 3.01** 2.79** 2.58*
Data are mean ± SD or median (range: 25 to 75 %). baPWV values are age- and gender-adjusted values (95 % confidence interval)
Unadjusted and Adjusted Ptrend values for linear trends across three groups are based on linear regression analysis for continuous variables or logistic regression
analysis for categorical variables. Model 1 and Adjusted Ptrend values for linear trends across three groups are based on linear regression analysis for continuous
variables or logistic regression analysis for categorical variables adjusted for age and gender. Model 2 and Adjusted Ptrend values for linear trends across three
groups are based on linear regression analysis for continuous variables or logistic regression analysis for categorical variables adjusted for age, gender, BMI,
morningness-eveningness questionnaire, Beck Depression inventory, energy intake, alcohol intake, current smoking, and physical activity. Model 3 and Adjusted
Ptrend values for linear trends across three groups are based on linear regression analysis for continuous variables adjusted for age, gender, BMI, morningness-
eveningness questionnaire, Beck Depression inventory, energy intake, alcohol intake, current smoking, physical activity, systolic BP, HbA1c, total cholesterol,
HDL-cholesterol, triglyceride and sleep duration
ALT alanine aminotransferase, AST aspartate aminotransferase, baPWV brachial-ankle pulse wave velocity, BP blood pressure, eGFR estimated glomerular filtration
rate, UAE urinary albumin excretion, HDL-C high-density lipoprotein-cholesterol, ɤ-GTP ɤ-glutamyl transpeptidase
*P < 0.05; **P < 0.01; ***P < 0.001
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Conclusions
In conclusion, our study demonstrated that poor sleep
quality in T2DM patients correlates with increased ar-
terial stiffness, a marker of atherosclerosis and a risk fac-
tor for CVD. While long-term prospective studies are
needed to confirm the study findings, the findings sug-
gest that poor sleep quality is an important target of
intervention in order to achieve appropriate manage-
ment of cardiovascular risk factors and prevent the pro-
gression of atherosclerosis in patients with T2DM.
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